Natera has begun the subject enrolment in the randomised Phase III SAGITTARIUS clinical trial designed to assess the ...

Natera (NTRA) announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC ...

JPMorgan analyst Rachel Vatnsdal raised the firm’s price target on Natera (NTRA) to $200 from $160 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect ...

Currently trading with a volume of 643,596, the NTRA's price is up by 3.63%, now at $172.49. RSI readings suggest the stock ...

德克萨斯州奥斯汀讯——根据向美国证券交易委员会提交的4表格显示，Natera, Inc.（纳斯达克股票代码：NTRA）临床诊断总裁Solomon Moshkevich最近进行了一笔重大的公司股票交易。Moshkevich于2024年12月9日以加权平均价格166.5937美元每股的价格出售了4,858股Natera普通股。此次出售的总价值约为809,312美元。根据 InvestingPro ...

Natera, Inc.（纳斯达克股票代码：NTRA）的董事Chapman Rowan ...

We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a ...

Natera, Inc. (NASDAQ:NTRA – Get Free Report) has earned an average rating of “Buy” from the seventeen ratings firms that are ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC ...

The latest announcement is out from Natera ( (NTRA) ).

AUSTIN, Texas, December 12, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS ...

According to Benzinga Pro, Natera's peer group average for short interest as a percentage of float is 5.09%, which means the ...